SCHEMBL3618151

SCHEMBL3618151

O=C(Nc1cnccc1C(=O)O)c1ccc(Cl)s1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 0.58
KDM4D Q6B0I6 3/20 0.58
PRSS12 P56730 3/20 0.52
KDM5A P29375 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
KMT2A Q03164 5/20 0.49
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
MEN1 O00255 4/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM6B O15054 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
DAO P14920 1/20 0.46
EGLN3 Q9H6Z9 1/20 0.46
LMNA P02545 1/20 0.46
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3620308 0.89 PRSS12 (0.51) KDM4CKDM4DPRSS12KMT2ANPC1
SCHEMBL3604192 0.86 KMT2A (0.57) KMT2ANPC1RAB9AMEN1HPGD
SCHEMBL4634602 0.81 KMT2A (0.46) PRSS12KMT2ANPC1RAB9AMEN1
SCHEMBL3614718 0.79 PRSS12 (0.52) PRSS12KMT2ANPC1RAB9AMEN1
SCHEMBL4634559 0.78 KMT2A (0.49) PRSS12KMT2ANPC1RAB9AMEN1
SCHEMBL3615049 0.78 KMT2A (0.57) PRSS12KMT2ANPC1RAB9AMEN1
SCHEMBL1308259 0.78 PRSS12 (0.63) PRSS12KMT2AMEN1HPGDALDH1A1
SCHEMBL4633505 0.76 KMT2A (0.49) KMT2ANPC1RAB9AMEN1HPGD
SCHEMBL15839748 0.75 KDM4C (0.73) KDM4CKDM4DKDM5BKDM6BKDM4E
SCHEMBL3618064 0.74 NPC1 (0.60) PRSS12KMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
EP-1928868-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF Bayer HealthCare AG (DE) 2008-06-11 EP disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use PPOX, XDH, PNPO KDM4C 3430/4885KDM4D 2446/4885PRSS12 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.